Download the White Paper

ConcertAI Takes a Leading Position
on Frost & Sullivan's "Frost Radar"

ConcertAI: Pioneering the Future of AI-Driven Clinical Trials

D01_ConcertAI-Frost-Radar-020426.png

According to Frost & Sullivan, ConcertAI has emerged as a transformative leader in AI-enabled clinical trials, "setting new benchmarks for innovation and operational excellence." Leveraging proprietary platforms like CARA and CancerLinQ, ConcertAI "specializes in research-ready data" and utilizes "generative and agentic AI" alongside real-world data to "streamline patient recruitment, optimize site selection, and automate end-to-end research workflows." With a strong focus on oncology and precision medicine, the company partners with leading life sciences and healthcare organizations to "shorten clinical trial timelines" and "drive efficiency, reduce costs, and accelerate clinical breakthroughs," solidifying its position as a global innovator.